Analyst Reco. Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Market Closed - Nasdaq Other stock markets 21:00:01 01/05/2024 BST			5-day change	1st Jan Change
398.4 ^USD	+2.58%		+0.21%	+29.96%

05-01	Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing	MT
04-24	Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing	05-01	MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating	04-24	MT
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450	04-23	MT
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target	03-18	MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating	03-08	MT
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282	02-15	MT
UBS Adjusts Medpace Price Target to $282 From $270, Maintains Neutral Rating	25/10/23	MT
Baird Upgrades Medpace Holdings to Outperform From Neutral, Adjusts Price Target to $289 From $270	24/10/23	MT
UBS Adjusts Medpace Price Target to $270 From $215, Maintains Neutral Rating	26/07/23	MT
Guggenheim Raises Medpace Holdings' Price Target to $273 From $252, Keeps Buy Rating	25/07/23	MT
Guggenheim Upgrades Medpace Holdings to Buy From Neutral, Price Target is $252	08/05/23	MT
UBS Lowers Price Target on Medpace to $215 From $238, Keeps Neutral Rating	10/04/23	MT
UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $238 From $142	27/10/22	MT
Baird Adjusts Medpace Holdings' Price Target to $217 From $200, Keeps Neutral Rating	26/10/22	MT
Baird Adjusts Price Target on Medpace Holdings to $200 From $145, Maintains Neutral Rating	25/10/22	MT
UBS Initiates Coverage on Medpace Holdings With Sell Rating, $142 Price Target	07/09/22	MT
Baird Lowers Price Target for Medpace Holdings to $137 From $151, Maintains Neutral Rating	13/06/22	MT
Guggenheim Initiates Coverage on Medpace Holdings With Neutral Rating	24/05/22	MT
MEDPACE : Truist Adjusts Price Target on Medpace Holdings to $200 From $193, Maintains Buy Rating	27/07/21	MT
MEDPACE : Credit Suisse Adjusts Medpace Holdings' Price Target to $205 from $200, Keeps Outperform Rating	20/07/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Medpace Holdings, Inc: A winning stock that went under the radar

June 29, 2022 at 03:45 pm